RxDoctor Payments Data

Shohan Shetty, MD

Surgery · Waterbury, CTNPI 1073772356

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (41.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Intuitive Surgical at 52.1% of the total.

$14,582in general payments, 2019–2025

Across 39 payments — averaging $373.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$8K
  • Davol Inc.$5K
  • Medtronic$2K
  • Baxter Healthcare$136
  • Novo Nordisk$18
  • Covidien LP$11

What the payments were for

  • Consulting fees$2,02514%
  • Speaking & faculty fees$5,10035%
  • Travel & lodging$6484%
  • Food & beverage$8096%
  • Education$6,00041%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical24$7,592
Davol Inc.5$4,702
Medtronic6$2,123
Baxter Healthcare2$136
Novo Nordisk1$18
Covidien LP1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,582 in reported general payments places this provider in the 85th percentile of 289 surgery providers in Connecticut.

See all surgery providers in Connecticut

Medicare billing

Part B allowed, 2024
$64,366
Medicare patients
138
Services billed
349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$24,579
OzempicSemaglutide15$13,068
Pantoprazole Sodium82$530
Metformin Hcl28$49

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$18$13,06815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 289 surgery providers in Connecticut.

Other surgery in Waterbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →